Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H27FO6 |
| Molecular Weight | 394.4339 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
InChI
InChIKey=GFNANZIMVAIWHM-OBYCQNJPSA-N
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
| Molecular Formula | C21H27FO6 |
| Molecular Weight | 394.4339 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Triamcinolone is a long-acting synthetic corticosteroid primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone diacetate injectable suspension is indicated for intramuscular use as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiform (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate ant tuberculous chemotherapy. For palliative management of leukemia’s and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate ant tuberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. As adjunctive therapy for short-term administration in acute gouty arthritis; acute rheumatic carditis. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins that, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors, which translocate into the nucleus, bind DNA (GRE), and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19744340 |
1.5 nM [IC50] | ||
Target ID: P04150 Gene ID: 2908.0 Gene Symbol: NR3C1 Target Organism: Homo sapiens (Human) Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D00984 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
| Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
| Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
| Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
| Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7202 ng/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE aqueous humor | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1911 ng × h/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE aqueous humor | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
18.7 day |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE aqueous humor | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
120 mg 1 times / day multiple, intramuscular Higher than recommended Dose: 120 mg, 1 times / day Route: intramuscular Route: multiple Dose: 120 mg, 1 times / day Sources: |
unhealthy, 28-57 |
|
360 mg single, intramuscular Highest studied dose Dose: 360 mg Route: intramuscular Route: single Dose: 360 mg Sources: |
unhealthy, 37.5 |
|
200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: |
unhealthy, 46 |
Disc. AE: Cushing's syndrome... AEs leading to discontinuation/dose reduction: Cushing's syndrome Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cushing's syndrome | Disc. AE | 200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: |
unhealthy, 46 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10570047/ |
weak |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | likely (co-administration study) Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with Kenalog-10 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions. Page: 10.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Intravitreal triamcinolone in recurrence of choroidal neovascularisation. | 2002-06 |
|
| Systemic effect comparisons of six inhaled corticosteroid preparations. | 2002-05-15 |
|
| CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture. | 2002-05 |
|
| Laser-induced weal and flare reactions: clinical aspects and pharmacological modulation. | 2002-05 |
|
| Intravitreal triamcinolone for refractory diabetic macular edema. | 2002-05 |
|
| Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. | 2002-05 |
|
| Local injection treatment for lateral epicondylitis. | 2002-05 |
|
| A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. | 2002-05 |
|
| Topical steroid therapy for phimosis. | 2002-04 |
|
| Intralesional triamcinolone for chondrodermatitis nodularis: a follow-up study of 60 patients. | 2002-04 |
|
| Spontaneous bleeding following steroid injection and silicone-gel sheeting in a keloid scar. | 2002-03 |
|
| Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus. | 2002-03 |
|
| Correction of the soft tissue pollybeak using triamcinolone injection. | 2002-02-15 |
|
| Stopping triamcinolone led to treatment failures in patients with persistent asthma who were receiving salmeterol and triamcinolone. | 2002-02-07 |
|
| Salmeterol was not as effective as triamcinolone for persistent asthma. | 2002-02-07 |
|
| [The effect of triamcinolone acetonide, montelukast, nedocromil sodium, formoterol on levels levels of sICAM-1, sIL-2R in serum and clinical course of asthma in children]. | 2002-02 |
|
| A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. | 2002-02 |
|
| Localized linear scleroderma with cutaneous calcinosis. | 2002-02 |
|
| Posterior retinal vasculitis associated with multiple sclerosis. | 2002-02 |
|
| Intralesional corticosteroids as an alternative treatment for central giant cell granuloma. | 2002-02 |
|
| Subcutaneous steroid injection as treatment for chalazion: prospective case series. | 2002-02 |
|
| Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. | 2002-02 |
|
| Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. | 2002-02 |
|
| Treating patients with hemiplegic shoulder pain. | 2002-02 |
|
| Safety of steroid injections in the treatment of nasofrontal recess obstruction. | 2002-01-05 |
|
| Shoulder joint capsule distension (hydroplasty): a case series of patients with "frozen shoulders" treated in a primary care office. | 2002-01 |
|
| Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. | 2002-01 |
|
| Selective corticosteroid injection into the extensor pollicis brevis tenosynovium for de Quervain's disease. | 2002-01 |
|
| Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. | 2002-01 |
|
| The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. | 2002-01 |
|
| Glucocorticoid epidural for sciatica: metabolic and endocrine sequelae. | 2002-01 |
|
| Two cases of morphea associated with Hashimoto's thyroiditis. | 2002 |
|
| Lichenoid sarcoidosis in a 3-year-old girl. | 2001-12-12 |
|
| Pericardial access using the PerDUCER and flexible percutaneous pericardioscopy. | 2001-12-01 |
|
| Symptomatic lumbar synovial cyst: management with direct CT-guided puncture and steroid injection. | 2001-12 |
|
| [Relevance of nerve blocks in treating and diagnosing low back pain--is the quality decisive?]. | 2001-12 |
|
| Injections and surgical therapy in chronic pain. | 2001-12 |
|
| Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up. | 2001-12 |
|
| Apoptosis of airway epithelial cells induced by corticosteroids. | 2001-11-15 |
|
| Plasma cell mucositis. | 2001-11 |
|
| Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice. | 2001-11 |
|
| Papular elastorrhexis in childhood improved by intralesional injections of triamcinolone. | 2001-10 |
|
| Cushing syndrome induced by serial occipital nerve blocks containing corticosteroids. | 2001-10 |
|
| Markers of allergic inflammation in peripheral blood of children with asthma after treatment with inhaled triamcinolone acetonide. | 2001-10 |
|
| Exacerbation of allergic contact dermatitis from amcinonide triggered by patch testing. | 2001-10 |
|
| [The effect of triamcinolone, montelukast and formoterol on serum levels of il-4, IgE and clinical parameters in children with asthma]. | 2001-09 |
|
| [Experiences with liposuction of established surgeons]. | 2001 |
|
| Cutaneous drug reaction case reports: from the world literature. | 2001 |
|
| Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. | 2001 |
|
| [Corticosteroid myopathy]. | 2001 |
Sample Use Guides
The initial intramuscular dosage of triamcinolone diacetate injectable suspension may vary from 3 to 48 mg per day depending on the specific disease entity being treated
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14406639
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:26:21 GMT 2025
by
admin
on
Mon Mar 31 21:26:21 GMT 2025
|
| Record UNII |
1ZK20VI6TY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QH02AB08
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QA01AC01
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
D07BB03
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
LIVERTOX |
994
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
R03BA06
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 524.1600B
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 522.2483
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QR01AD11
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
NDF-RT |
N0000175450
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QD07AB09
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
A01AC01
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 524.2483
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
D07XB02
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
R01AD11
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
H02AB08
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
NDF-RT |
N0000175576
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 524.2482
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QD07CB01
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 524.1600A
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QD07BB03
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QD07XB02
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
S02CA04
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QC05AA12
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 520.2483
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QR03BA06
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
D07CB01
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QS01BA05
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QS02CA04
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
S01BA05
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
C05AA12
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
D07AB09
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C901
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
2725
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
100000092178
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
1ZK20VI6TY
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
755
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
TRIAMCINOLONE
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
Triamcinolone, Topical
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
DB00620
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
124-94-7
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
m11027
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
2870
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
SUB11251MIG
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL1451
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
1676000
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
9667
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
Triamcinolone
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
10759
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
13397
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
31307
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
DTXSID1040742
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
1ZK20VI6TY
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
3194
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
204-718-7
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
D014221
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
TRANSPORTER -> SUBSTRATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|